Neurocrine Bio. (NBIX) PT Lowered to $123 at RBC Capital
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $156.58 +0.01%
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $123.00 (from $136.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Raised to $183 at Morgan Stanley
- Oracle (ORCL) PT Lowered to $200 at Stifel, Buy Rating Maintained
- The Lovesac Co. (LOVE) PT Lowered to $18 at DA Davidson as Guidance Lowered
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
